Cargando…

Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial

Introduction: ACT DMD was a 48‐week trial of ataluren for nonsense mutation Duchenne muscular dystrophy (nmDMD). Patients received corticosteroids for ≥6 months at entry and stable regimens throughout study. This post hoc analysis compares efficacy and safety for deflazacort and prednisone/prednisol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shieh, Perry B., Mcintosh, Joseph, Jin, Fengbin, Souza, Marcio, Elfring, Gary, Narayanan, Siva, Trifillis, Panayiota, Peltz, Stuart W., Mcdonald, Craig M., Darras, Basil T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767037/ https://www.ncbi.nlm.nih.gov/pubmed/30028519 http://dx.doi.org/10.1002/mus.26191

Ejemplares similares

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials
por: McDonald, Craig M., et al.
Publicado: (2019)

Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022)

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
por: Griggs, Robert C., et al.
Publicado: (2016)

Longitudinal Evaluation of Working Memory in Duchenne Muscular Dystrophy
por: Thangarajh, Mathula, et al.
Publicado: (2020)

Deflazacort Versus Prednisolone: Randomized Controlled Trial in Treatment of Children With Idiopathic Nephrotic Syndrome
por: Singhal, Ravish, et al.
Publicado: (2015)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Prednisone and Prednisolone in the Treatment of Rheumatoid Arthritis
por: Montgomery, D. A. D.
Publicado: (1957)

Optimising prednisolone or prednisone replacement in adrenal insufficiency
por: Sharma, Angelica, et al.
Publicado: (2023)

Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome
por: Schijvens, Anne M., et al.
Publicado: (2018)

Perception and usage of short-term prednisone and prednisolone in dogs
por: Gober, Margaret, et al.
Publicado: (2023)

Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life?
por: Sienko, Susan, et al.
Publicado: (2016)

Deflazacort-induced Acneiform Eruptions
por: Bashir, Mohammed Shakeel Mohammed, et al.
Publicado: (2017)

Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment
por: McDonald, Craig M., et al.
Publicado: (2021)

Four Case Reports of Acute Psychosis Secondary to Low Doses of Prednisone/Prednisolone
por: Lesko, Aquila, et al.
Publicado: (2021)

Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years’ experience in a South Indian teaching hospital
por: Petnikota, Harish, et al.
Publicado: (2016)

DEFLAZACORT VERSUS OTHER GLUCOCORTICOIDS: A COMPARISON
por: Nayak, Surajit, et al.
Publicado: (2008)

Deflazacort in comparison to other steroids for nephrotic syndrome
por: Jat, K. R., et al.
Publicado: (2012)

Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone
por: Fappi, Alan, et al.
Publicado: (2019)

Urinary excretion profile of prednisolone and prednisone after rectal administration: Significance in antidoping analysis
por: Iannella, Loredana, et al.
Publicado: (2022)

Deflazacort for the treatment of Duchenne Dystrophy: A systematic review
por: Campbell, Craig, et al.
Publicado: (2003)

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Deflazacort for Type-1 Autoimmune Hepatitis in a Korean Girl
por: Bae, Sun Hwan, et al.
Publicado: (2006)

Toxic epidermal necrolysis associated with deflazacort therapy with nephrotic syndrome
por: Lee, Eun Chae, et al.
Publicado: (2014)

Expeditious synthesis and preliminary antimicrobial activity of deflazacort and its precursors
por: Esposito, Anna, et al.
Publicado: (2019)

In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort
por: Ma, Jiyuan, et al.
Publicado: (2021)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy
por: Rotundo, Ida Luisa, et al.
Publicado: (2011)

The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy
por: McADAM, LAURA C., et al.
Publicado: (2012)

DMD & BMD – CLINICAL: P.51 DMD Hub: demonstrating impact for DMD trials
por: Heslop, E., et al.
Publicado: (2020)

Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
por: Walter, Maggie C, et al.
Publicado: (2013)

Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids
por: Parente, Luca
Publicado: (2017)

The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy
por: Dubinin, Mikhail V., et al.
Publicado: (2020)

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy
por: Jensen, L., et al.
Publicado: (2017)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Pseudoexons of the DMD Gene
por: Keegan, Niall P.
Publicado: (2020)

DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype
por: Wang, Richard T., et al.
Publicado: (2018)

Effect of deflazacort on pregnancy outcome in kidney transplant patients: should we change the immunosuppressant before conception?
por: Yun, Bo Hyon, et al.
Publicado: (2019)

Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention
por: Tyagi, Rahul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qmkkfb1b5s1dfueb192qndrlsd